PC‑3 human prostate cancer cell line was stained with Goat Anti-Human TGF‑ beta RIII Antigen Affinity‑purified Polyclonal Antibody (Catalog # AF‑242‑PB, filled histogram) or isotype control antibody (Catalog ...read more
Mouse myeloma cell line NS0-derived recombinant human TGF‑ beta RIII Gly21-Asp781 Accession # AAA67061
Detects human TGF-beta RIII in direct ELISAs and Western blots. In direct ELISAs, approximately 25% cross-reactivity with recombinant mouse (rm) TGF-beta RIII is observed, and less than 1% cross-reactivity with recombinant human (rh) TGF-beta RI, rhTGF-beta RII, rhTGF-beta RIIB, and rmTGF-beta RI is observed.
Immunogen affinity purified
Test in a species/application not listed above to receive a full credit towards a future purchase.
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Immunogen affinity purified
Reconstitute at 0.2 mg/mL in sterile PBS.
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for TGF-beta RIII Antibody
TGF-beta receptor type 3
TGF-beta receptor type III
Transforming growth factor beta receptor III
transforming growth factor beta receptor type 3
transforming growth factor, beta receptor III (betaglycan, 300kDa)
transforming growth factor, beta receptor III
Most cell types express three sizes of receptors for TGF-beta. These are designated Type I (53 kDa), Type II (70-85 kDa), and Type III (250-350 kDa). The Type I receptor is a membrane-bound serine/threonine kinase that apparently requires the presence of the Type II receptor to bind TGF-beta. The Type II receptor is also a membrane-bound serine/threonine kinase that binds TGF-beta 1 and TGF-beta 3 with high affinity and TGF-beta 2 with a much lower affinity. The Type I and Type II receptors together form a heterodimeric signaling complex that is essential for the transduction of the anti-proliferative signals of TGF-beta.
The Type III receptor is a transmembrane proteoglycan with a large extracellular domain and a 43 amino acid residue cytoplasmic domain. The cytoplasmic domain of the Type III receptor lacks an obvious signaling motif and the receptor may not be involved directly in signal transduction. The Type III receptor binds TGF-beta 2 with the highest affinity. Other TGF-beta isoforms also bind the Type III receptor, but with lower affinities. Cellular responsiveness to TGF-beta 2 appears to be dependent on the presence of the Type III receptor which can interact with the signaling receptor complex. In addition to the transmembrane Type III receptor, a soluble form of the receptor is secreted by some cell types. The physiological role of this soluble receptor remains to be determined. The recombinant TGF-beta soluble receptor Type III binds the TGF-beta isoforms differentially in solution and exhibits TGF-beta antagonistic activities in vitro.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our TGF-beta RIII Antibody and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.